Multaq REMS May Be Revamped As Label Adds New Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
After several years of regulatory struggles Sanofi’s anti-arrhythmic Multaq finally got to market. But results from a new study have drawn attention to safety problems in higher-risk patients and could damage the drug’s commercial opportunity.